AG2R LA Mondiale Gestion D Actifs Purchases Shares of 210,530 Pfizer Inc. $PFE

Key Points

• AG2R LA Mondiale Gestion D Actifs acquired 210,530 shares of Pfizer Inc. for approximately $4.945 million during the first quarter.
• Pfizer's latest earnings report showed $0.78 earnings per share, exceeding analysts' expectations, with revenue of $14.65 billion for the quarter.
• The company announced a quarterly dividend of $0.43 per share, translating to an annualized yield of 6.9%.

AG2R LA Mondiale Gestion D Actifs purchased a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 210,530 shares of the biopharmaceutical company's stock, valued at approximately $4,945,000.

Several other large investors have also added to or reduced their stakes in the company. Bessemer Group Inc. lifted its holdings in shares of Pfizer by 11.1% in the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after buying an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK lifted its holdings in shares of Pfizer by 1.2% in the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock worth $35,817,000 after buying an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp purchased a new position in shares of Pfizer in the first quarter worth $8,283,000. Alta Advisers Ltd lifted its holdings in shares of Pfizer by 69.6% in the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock worth $809,000 after buying an additional 13,100 shares in the last quarter. Finally, WCM Investment Management LLC lifted its holdings in shares of Pfizer by 8.7% in the first quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock worth $3,176,000 after buying an additional 10,051 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 1.1%

PFE stock opened at $24.84 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The stock has a market capitalization of $141.23 billion, a price-to-earnings ratio of 13.21, a price-to-earnings-growth ratio of 0.87 and a beta of 0.55. The firm's fifty day simple moving average is $24.82 and its two-hundred day simple moving average is $24.32.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the previous year, the business posted $0.60 earnings per share. The business's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer's payout ratio is 91.49%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on PFE shares. Bank of America boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. HSBC lowered their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Berenberg Bank decreased their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Jefferies Financial Group upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. Finally, Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.